FINDINGS
We performed a meta-analysis of multicenter cohort studies of the effects of EBD for CDassociated strictures of the UGI tract. Technical and short term clinical success rates were of 100% and 87%, respectively, although major complications arose from 2.9% of procedures.
During a median follow up period of 23.1 months, 70.5% of patients had recurrence of symptoms, 59.6% underwent re-dilation, and 30.8% of patients required surgery. Patients with disease locations in the small bowel had a higher hazard for symptom recurrence and need for re-dilation. Pre-stenotic dilation was a risk factor for earlier need for surgery.
IMPLICATIONS FOR PATIENT CARE
In a meta-analysis, we found EBD for CD-associated strictures of the UGI to be a valuable alternative to surgery, with a high rate of short-term technical and clinical success, moderate long-term efficacy, and an acceptable rate of complications.
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INTRODUCTION
Crohn's disease (CD) may affect the entire gastrointestinal (GI) tract (1) . As a consequence of transmural inflammation and a relapsing and remitting disease course, clinically apparent fibrostenosis of the intestine occurs in 20% of patients within 20 years after initial diagnosis (2) . Despite recent advances in the medical treatment of CD, prevention and treatment of stricturing CD remains a large unmet need (3) . Due to the absence of specific anti-fibrotic therapies (4), CD patients with intestinal obstruction are commonly treated by surgical intervention such as strictureplasty or bowel resection (5) , both of which can be associated with significant complications (6, 7) .
While CD may affect all parts of the GI tract, involvement of the stomach and duodenum is rarely reported. More specifically, the incidence of CD-associated strictures of the upper GI tract is below 4% (8) . Beside the occurrence of strictures, fistulae development in the upper GI tract has been reported as well (9, 10). Historically, in the pre-steroid era, surgery was the solely available treatment modality for obstructive duodenal CD, but was often accompanied by a complicated postoperative course with postoperative abscesses (11, 12) . Subsequently, with the advent of corticosteroids and immunosuppressive drugs, some case reports are available that illustrate cases with a -at least temporary -successfully medical treatment (8, 9, 11) . Therefore, stricturing as well as fistulizing complications of the upper GI tract may generate challenging clinical scenarios for both, affected CD patients as well as health care providers alike. The very limited body of published evidence for this treatment scenario is further aggravating this clinical dilemma.
Endoscopic balloon dilation (EBD) has emerged as an alternative to surgery and has been proven effective for the treatment of fibrotic CD-associated strictures of the ileocecum. EBD M A N U S C R I P T
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6 has therefore been implemented in current CD treatment algorithms and guidelines (13-15).
EBD for CD-associated strictures of the upper GI tract is rarely reported, with the largest cohort comprising 35 patients from a single center (16). Therefore, the aim of this pooled analysis of international multicenter cohort studies, combining published cohorts with a multicenter investigation for a patient level meta-analysis, was to evaluate safety and efficacy of EBD in upper GI Crohn's disease associated strictures, in order to provide evidence-based guidance for this clinical situation.
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METHODS AND MATERIAL
Literature search and data
Detailed information regarding the literature search and data, as well as a PRISMA diagram (Supplemental Figure 1) can be found in the supplement. Corresponding authors of papers that fulfilled the inclusion and exclusion criteria were contacted via e-mail to obtain single patient level data of the subjects included in the studies. These data represent part one of the pooled individual patient analysis.
In addition, 7 high volume inflammatory bowel disease (IBD) endoscopy centers were contacted and provided clinical data of cumulative 24 patients. These data represent part two of the pooled individual patient analysis. Of note, comparable criteria were used to assess the performance of dilation procedures as well as treatment outcomes in relation to the already published studies and as defined below.
Data collection
Used definitions for the explored of included studies (16-19) were reported in the   supplemental text and supplemental table 1, Tables 2 & 3 in detail.
Statistical analysis
Detailed information about the statistical analysis can be found in the supplement.
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RESULTS
Pooled individual patient analysis
In total, we included 94 patients from 11 different tertiary referral centers for IBD (located in the United States, Australia, China, Japan, Denmark, Germany, Netherlands and Switzerland).
The number of total dilation procedures was 141. 70 patients undergoing 112 dilations have been published in multiple individual smaller series prior (16-21) and 24 patients undergoing 29 dilations were not previously published and added through our multicenter collaboration (Table 1 ). The demographics of this population are depicted in Table 2 . The median age at diagnosis of CD was 24 ± 10.6 years while the median age at time of stricture diagnosis was 33.7 ± 14.3 years. 75.9% of strictures were located in the duodenum, 21.3% of patients developed strictures in the stomach and 2.8% of patients presented with strictures that spanned from the stomach to the duodenum ( 
months, 70.5% of patients reported symptomatic recurrence, 59.6% required another dilation and 30.8% of all patients had to undergo surgical intervention (Table 2, 3 and Fig. 1 A-C). Table 1 presents descriptive statistics for patients from each center as well as the random effects analysis and measures of variability. The overall rates for symptom, dilation and surgery free survival at 6, 12 and 24 months are depicted in Table 4 .
To assess potential bias, we included both published and unpublished studies (Suppl . Tables   2a, 3a , 4a and 5a) and performed a sensitivity analysis separately after excluding unpublished studies (Suppl. Tables 2b, 3b, 4b and 5b). These results are presented and discussed in the supplement to this article and the below data refers to the complete cohort only.
Factors associated with short-term dilation outcome
Given the achievement of technical success in all included subjects, no analysis for factors associated with technical success could be performed. We hence evaluated factors associated with short term clinical efficacy of dilation procedures. Patients with active disease in the ileocecum had a lower likelihood of relief of symptoms in the adjusted and unadjusted analysis (OR 0.27, confidence interval (CI)95%: 0.058-1.2; p=0.087 and OR 0.27, CI95%:
0.06 -1.2; p=0.083). No other factor was linked to clinical efficacy (Supplemental Table 2a ).
Factors associated with symptom recurrence
We next assessed factors associated with symptom recurrence. In univariate analysis, disease location in the jejunum/proximal ileum (Hazard ratio (HR) 1.8; CI95%: 1.09-2.9; p=0.022)
was associated with an increased hazard for symptom recurrence. In contrast, a stricture length of less than 5 cm (HR 0.41; CI95%: 0.24-0.7; p=0.001) was negatively associated with time to symptom recurrence. While disease location in the jejunum/ileum was linked to M A N U S C R I P T A C C E P T E D Table 3a ).
Factors associated with need for re-dilation
Regarding the need for re-dilation, univariate as well as multivariate analysis showed that Asian race (HR 2.8; CI95%: 1.7-4.5; p<0.001 and HR 2.8; CI95%: 1.8-4.5; p<0.001) and disease location in the jejunum/proximal ileum (HR 1.7; CI95%: 1.1-2.6; p=0.015 and HR 1.9; CI95%: 1.2-2.9; p=0.004) were associated with a significantly increased risk of redilation (Supplemental Table 4a ). None of the other investigated factors, including smoking, stricture location, type of stricture (de novo vs. anastomotic), prestenotic dilation, graded dilation or maximum caliber of dilation or anti-TNF treatment were linked to the need for additional endoscopic therapy in the univariate or multivariate analysis (Supplemental Table   4a ).
Factors associated with the need for surgery
Prestenotic dilation was linked to an increased risk for surgery in the univariate as well as multivariate analysis (HR2.0; CI95%: 1.4-2.7, p<0.001 and HR 1.9; CI95%: 1.3-2.7; p=0.001;
Supplemental Table 5a ). In addition, in the univariate analysis, Asian race and younger age at time of dilation were found to be associated with an increased risk for surgery (HR 1.7; CI95: Table 5a ).
Complications after EBD
Complications associated with dilations occurred in 5 patients. This included 2 perforations and 3 bleeding events. No patient had to undergo dilation-associated surgery. Due to the low number of complications in the cohort, no meaningful analysis for risk factors could be performed. The patients that experienced a perforation were treated by their first dilation procedure, the stricture length was below 5 cm and both patients did not receive steroid treatment at the time of intervention.
Efficacy of serial dilations of upper GI strictures
Finally, we analyzed the efficacy of repeat dilations of the same stricture. Data on a second dilation were available for 22 episodes and a third dilation for 9 episodes. With regard to the technical success, all second and third dilations were successful. While a symptomatic relief of symptoms could be achieved in 86.2% of patients through the first dilation, clinical success was found in 85% of patients being treated by a second dilation and 88.9% of patients requiring a third dilation. The need for re-dilation was documented in 61.6% of patients following the first dilation and in 54.5% and 66.7% of patients being treated by a second and third dilation (all p>0.05). Interestingly, time to re-dilation did not differ significantly between first, second and third dilation procedure (p>0.05; Supplemental Table 6 ). Patients with small bowel disease location had a higher hazard for symptom recurrence and need for re-dilation. Pre-stenotic dilation was found to be risk factors for earlier need for surgery.
The largest pooled analysis of EBD for ileocecal strictures reported technical and clinical success rates of 89.1% and 80.8% (14). Our study shows that dilation therapy for CDassociated strictures of the upper GI tract is comparably successful in the short term. The very high technical success rate observed in our study may result from the fact that we defined this parameter differently from prior studies by the ability to dilate the stricture after starting the M A N U S C R I P T
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13 procedure (but not by the ability to traverse the stricture after dilation). During a follow up period of 23 months, long-term outcome parameters for dilation of CD-associated strictures of the upper GI tract such as symptoms recurrence, need for re-dilation and surgery were not significantly different as compared to pooled data for CD-associated strictures of the ileocecum during a follow up of 24 months (70.5 vs. 75.9%; 59.6 vs. 73.5% and 30.8 vs.
42.9%) (14), which came as a surprise, given the common belief of clinicians that upper GI CD-associated stricture dilation is less durable. Finally, the complications rates per dilation procedure for ileocecal and upper GI strictures were comparable (2.8% vs. 2.9%) (14). These results are also in line with the findings from other meta-analyses on EBD for CD-associated strictures (22, 23) . We were not able to assess if fluoroscopy impacted the complications rates of EBD as the vast majority of investigators reported to use fluoroscopy at the discretion of the operator and did not record its performance systematically. Taken together, our study provides evidence that endoscopic dilation of CD-associated strictures of the upper GI tract by EBD is effective and safe, with rates comparable to dilation therapy for CD-associated strictures of the ileocecum.
Identification of predictive factors for the long-term success of EBD of the upper GI tract would allow risk stratification of patients benefitting from a procedure. Patients with disease location in jejunum/proximal ileum showed a higher rate of symptom recurrence and need for re-dilation. The patients with pre-stenotic dilation were at a higher risk for surgery. Prestenotic dilation is a feature that is not observed in every patient with stricturing CD but is regarded as a sign of advanced, longer standing strictures with a higher fibrotic component, even though evidence supporting this notion is limited. In our cohort, patients' symptoms were less likely to improve when pre-stenotic dilation was present and the time to surgery was shorter. This is in concordance with the recently published CREOLE study, which evaluated the efficacy of anti-TNF treatment for symptomatic small-bowel strictures (3). Patients with M A N U S C R I P T
14 pre-stenotic dilation were at an increased risk for surgery. As jejunal/proximal ileal disease was found to be negatively associated with symptom recurrence and need for re-dilation, it can be hypothesized that CD patients with disease manifestation at different locations along the GI tract may suffer from a more severe phenotype or symptoms classified as obstructive originating from other regions of the GI tract. This assumption is supported by data from population-based studies indicating that CD patients with ileal involvement at time of diagnosis are at an increased risk for a more aggressive disease phenotype (2). Interestingly, race showed an effect on dilation efficacy. Aside from the fact that Asians may have a higher risk for stricture recurrence it may be explained by different strategies for the utilization of endoscopy and management strategy in this region.
Interestingly, active smoking was not found to be a risk factor for worse outcome of dilation therapy in our study. There is a body of evidence indicating the smoking aggravates the course of CD (24, 25) , increases the risk of postoperative recurrence (26, 27 ) and smoking cessation decreases the risk for CD-related surgery (28). One studies reports an increased risk for stricture recurrence after endoscopic dilation, however, the included patients exclusively suffered from ileocecal strictures (29).
Given the fact that stricture development follows the location of inflammation, it is logical that an early appropriate medical treatment of inflammatory CD of the upper GI tract may be the best approach to prevent the occurrence of CD-associated strictures. Overall estimates are obtained using survey methodology with study as a clustering effect.
Overall estimates: pooled estimate (95% CI). 
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SUPPLEMENT
Statistical analysis
Individual patient data meta-analysis was performed using a one-step approach where data from all studies were modeled simultaneously. Summary data was obtained using survey methodology with study as a clustering effect. In addition, regression accounts for correlations between subjects within the same study as well as multiple dilations for same patients. Complete-case analysis was performed. Short term Clinical Efficacy. Dilation-level data was used to assess factors associated with clinical efficacy using generalized linear mixed models with a logit link for binary data; random effects for center, study and subject were used to account for correlation between multiple dilations performed on the same patient and between patients seen at the same center. Only unadjusted analysis was performed as < 20 For the individual per-patient analysis a protocol was developed and items regarding demographics, disease phenotype, medications and dilation procedures were collected for all included subjects. A detailed list depicting all assessed variables is shown in Tables 2 & 3 .
Since the organizers of this article did not have access to the individual patient charts we used the descriptors provided by the investigators and no patient was re-classified.
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